Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 1
2009 1
2010 3
2011 2
2012 4
2013 3
2014 5
2015 4
2016 6
2017 7
2018 6
2019 2
2020 7
2021 7
2022 4
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts.
Stacchiotti S, Dürr HR, Schaefer IM, Woertler K, Haas R, Trama A, Caraceni A, Bajpai J, Baldi GG, Bernthal N, Blay JY, Boye K, Broto JM, Chen WT, Dei Tos PA, Desai J, Emhofer S, Eriksson M, Gronchi A, Gelderblom H, Hardes J, Hartmann W, Healey J, Italiano A, Jones RL, Kawai A, Leithner A, Loong H, Mascard E, Morosi C, Otten N, Palmerini E, Patel SR, Reichardt P, Rubin B, Rutkowski P, Sangalli C, Schuster K, Seddon BM, Shkodra M, Staals EL, Tap W, van de Rijn M, van Langevelde K, Vanhoenacker FMM, Wagner A, Wiltink L, Stern S, Van de Sande VM, Bauer S. Stacchiotti S, et al. Among authors: boye k. Cancer Treat Rev. 2023 Jan;112:102491. doi: 10.1016/j.ctrv.2022.102491. Epub 2022 Dec 6. Cancer Treat Rev. 2023. PMID: 36502615 Free article. Review.
Multimodal kreftbehandling av gastrointestinal stromal tumor.
Hompland I, Hølmebakk T, Boye K, Stoldt S, Bjerkehagen B, Berner JM, Wiedswang AM, Revheim ME, Poulsen JP, Hall KS, Bruland ØS. Hompland I, et al. Among authors: boye k. Tidsskr Nor Laegeforen. 2018 Oct 1;138(15). doi: 10.4045/tidsskr.18.0200. Print 2018 Oct 2. Tidsskr Nor Laegeforen. 2018. PMID: 30277049 Free article. Review. Norwegian.
Sarcoma care in the era of precision medicine.
Wallander K, Öfverholm I, Boye K, Tsagkozis P, Papakonstantinou A, Lin Y, Haglund de Flon F. Wallander K, et al. Among authors: boye k. J Intern Med. 2023 Dec;294(6):690-707. doi: 10.1111/joim.13717. Epub 2023 Sep 7. J Intern Med. 2023. PMID: 37643281 Review.
Prospects for NK Cell Therapy of Sarcoma.
Lachota M, Vincenti M, Winiarska M, Boye K, Zagożdżon R, Malmberg KJ. Lachota M, et al. Among authors: boye k. Cancers (Basel). 2020 Dec 11;12(12):3719. doi: 10.3390/cancers12123719. Cancers (Basel). 2020. PMID: 33322371 Free PMC article. Review.
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study.
Gelderblom H, Jones RL, Blay JY, George S, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Siontis BL, Goldstein D, Boye K, Sanchez C, Steeghs N, Rutkowski P, Druta M, Serrano C, Somaiah N, Chi P, Harrow B, Becker C, Reichmann W, Sherman ML, Ruiz-Soto R, Heinrich MC, Bauer S; INTRIGUE investigators. Gelderblom H, et al. Among authors: boye k. Eur J Cancer. 2023 Oct;192:113245. doi: 10.1016/j.ejca.2023.113245. Epub 2023 Jul 20. Eur J Cancer. 2023. PMID: 37598656 Free article. Clinical Trial.
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.
Heinrich MC, Jones RL, George S, Gelderblom H, Schöffski P, von Mehren M, Zalcberg JR, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Siontis BL, Goldstein D, Boye K, Sanchez C, Steeghs N, Rutkowski P, Druta M, Serrano C, Somaiah N, Chi P, Reichmann W, Sprott K, Achour H, Sherman ML, Ruiz-Soto R, Blay JY, Bauer S. Heinrich MC, et al. Among authors: boye k. Nat Med. 2024 Feb;30(2):498-506. doi: 10.1038/s41591-023-02734-5. Epub 2024 Jan 5. Nat Med. 2024. PMID: 38182785 Free PMC article. Clinical Trial.
Diagnostics and Treatment of Extrameningeal Solitary Fibrous Tumors.
Janik AM, Terlecka A, Spałek MJ, Boye K, Szostakowski B, Chmiel P, Szumera-Ciećkiewicz A, Bobak K, Świtaj T, Rutkowski P, Czarnecka AM. Janik AM, et al. Among authors: boye k. Cancers (Basel). 2023 Dec 15;15(24):5854. doi: 10.3390/cancers15245854. Cancers (Basel). 2023. PMID: 38136399 Free PMC article. Review.
Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden.
Peneder P, Stütz AM, Surdez D, Krumbholz M, Semper S, Chicard M, Sheffield NC, Pierron G, Lapouble E, Tötzl M, Ergüner B, Barreca D, Rendeiro AF, Agaimy A, Boztug H, Engstler G, Dworzak M, Bernkopf M, Taschner-Mandl S, Ambros IM, Myklebost O, Marec-Bérard P, Burchill SA, Brennan B, Strauss SJ, Whelan J, Schleiermacher G, Schaefer C, Dirksen U, Hutter C, Boye K, Ambros PF, Delattre O, Metzler M, Bock C, Tomazou EM. Peneder P, et al. Among authors: boye k. Nat Commun. 2021 May 28;12(1):3230. doi: 10.1038/s41467-021-23445-w. Nat Commun. 2021. PMID: 34050156 Free PMC article.
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?
van Ewijk R, Cleirec M, Herold N, le Deley MC, van Eijkelenburg N, Boudou-Rouquette P, Risbourg S, Strauss SJ, Palmerini E, Boye K, Kager L, Hecker-Nolting S, Marchais A, Gaspar N; FOSTER Consortium (Fight OsteoSarcoma Through European Research), work package 3 on recurrent/refractory osteosarcoma trials. van Ewijk R, et al. Among authors: boye k. Cancer Treat Rev. 2023 Nov;120:102625. doi: 10.1016/j.ctrv.2023.102625. Epub 2023 Sep 15. Cancer Treat Rev. 2023. PMID: 37738712 Free article. Review.
64 results